1228108-65-3

Basic information

• Product Name: BI-97C1
• Synonyms: BI-97C1;Sabutoclax;(1R)-1,1',6,6',7,7'-Hexahydroxy-3,3'-dimethyl-N5,N5'-bis[(2R)-2-phenylpropyl]-[2,2'-binaphthalene]-5,5'-dicarboxamide;[2,2'-Binaphthalene]-5,5'-dicarboxamide, 1,1',6,6',7,7'-hexahydroxy-3,3'-dimethyl-N5,N5'-bis[(2R)-2-phenylpropyl]-, (1R)
• CAS NO: 1228108-65-3
• Molecular Formula: C₄₂H₄₀N₂O₈
• Molecular Weight: 700.7756
• Product Categories: Inhibitors
• Mol File: 1228108-65-3.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 905.9±65.0 °C(Predicted)
• Appearance: /
• Density: 1.358±0.06 g/cm3(Predicted)
• Storage Temp.: -20°C Freezer
• Solubility: DMSO (Slightly), Ethyl Acetate (Slightly), Methanol (Slightly)
• PKA: 7.35±0.50(Predicted)
• CAS DataBase Reference: BI-97C1(CAS DataBase Reference)
• NIST Chemistry Reference: BI-97C1(1228108-65-3)
• EPA Substance Registry System: BI-97C1(1228108-65-3)

Safety Data

• Hazardous Substances Data: 1228108-65-3(Hazardous Substances Data)

Usage

Description

BI-97C1, also known as Sabutoclax, is a pan-Bcl-2 inhibitor that targets multiple anti-apoptotic Bcl-2 family proteins, including Bcl-xL, Bcl-2, Mcl-1, and Bfl-1. It exhibits potent inhibitory activity with IC50 values of 0.31 μM, 0.32 μM, 0.20 μM, and 0.62 μM, respectively. Sabutoclax has emerged as a promising therapeutic agent for inducing mitochondrial fragmentation and apoptosis in cancer cells.

Uses

Used in Oncology:
BI-97C1 is used as a pan-Bcl-2 inhibitor for targeting anti-apoptotic Bcl-2 family proteins in cancer cells. Its ability to induce mitochondrial fragmentation and apoptosis makes it a potential therapeutic agent for various cancer types.
Used in Cancer Research:
BI-97C1 is used as a novel putative MCL-1 inhibitor in cancer research to study the mechanisms of mitochondrial fragmentation and apoptosis induction in cancer cells. This helps in understanding the role of Bcl-2 family proteins in cancer progression and identifying potential therapeutic targets.

Biological Activity

sabutoclax is an inhibitor of pan-bcl-2 family with ic50 values of 0.32, 0.31, 0.20 and 0.62 μm for bcl-2, bcl-xl, mcl-1 and bfl-1, respectively [1].sabutoclax is a derivative of apogossypolone. it showed a high binding affinity to bcl-xl both in nmr binding assay and in itc assay, with a kd value of 0.11μm. sabutoclax also showed better cell membrane permeability than other apogossypolone derivatives. in pc3 cells, sabutoclax inhibited cell growth with ec50 value of 0.13 μm. in human bp3 cell line, sabutoclax induced cell apoptosis with ic50 value of 0.049 μm. in mice bearing m2182 cancer xenografts, administration of sabutoclax significantly reduced the tumor size. at dose of 5 mg/kg, sabutoclax induced near complete tumor growth suppression [1].

references

[1] wei j, stebbins j l, kitada s, et al. bi-97c1, an optically pure apogossypol derivative as pan-active inhibitor of antiapoptotic b-cell lymphoma/leukemia-2 (bcl-2) family proteins. journal of medicinal chemistry, 2010, 53(10): 4166-4176.

Upstream product

• 1173895-39-0 1,1',6,6',7,7'-hexamethoxy-3,3'-dimethyl-N₅,N₅'-bis(2-phenylpropyl)-2,2'-binaphthyl-5,5'-dicarboxamide 
• 303-45-7 (rac)-gossypol 
• 784206-41-3 apogossypol 
• 7144-61-8 5,5'-diisopropyl-1,1',6,6',7,7'-hexamethoxy-3,3'-dimethyl-2,2'-binaphthalene 
• 96964-27-1 1,1',6,6',7,7'-hexamethoxy-3,3'-dimethyl-<2,2'-binaphthalene>-5,5'-dicarboxaldehyde 

Downstream Products

• 1256723-98-4 6,6',7,7'-tetrahydroxy-3,3'-dimethyl-1,1',4,4'-tetraoxo-N₅,N₅'-bis(2-phenylpropyl)-1,1',4,4'-tetrahydro-2,2'-binaphthyl-5,5'-dicarboxamide 

Relevant articles and documents

Synthesis and biological evaluation of apogossypolone derivatives as pan-active inhibitors of antiapoptotic B-cell lymphoma/leukemia-2 (Bcl-2) family proteins

Overexpression of antiapoptotic Bcl-2 family proteins is commonly related with tumor maintenance, progression, and chemoresistance. Inhibition of these antiapoptotic proteins is an attractive approach for cancer therapy. Guided by nuclear magnetic resonan

Apogossypol derivatives as pan-active inhibitors of antiapoptotic B-cell lymphoma/leukemia-2 (Bcl-2) family proteins

Guided by nuclear magnetic resonance (NMR) binding assays and computational docking studies, a series of 5,5′ substituted apogossypol derivatives was synthesized that resulted in potent pan-active inhibitors of antiapoptotic Bcl-2 family proteins. Compoun